Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 05, 2019 16:30 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM Mass. and CRESTWOOD, Ky., April 05, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Resumes Dosing in Its Phase 3 Program for Patients with Geographic Atrophy
March 04, 2019 07:00 ET
|
Apellis Pharmaceuticals, Inc.
No inflammation observed in ten patients dosed in Phase 1b trial with new intravitreal APL-2 drug product from modified manufacturing process CRESTWOOD, Ky. and WALTHAM, Mass., March 04, 2019 ...
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
February 26, 2019 17:00 ET
|
Apellis Pharmaceuticals, Inc.
Phase 3 Geographic Atrophy Program Expected to Restart By or In Q2 2019 Phase 3 Trial of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria Expected to be Fully Enrolled by End of Q2 2019 ...